ASH 2020 | KarMMa-4: ide-cel for newly diagnosed high-risk multiple myeloma
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, introduces the KarMMa-4 trial (NCT04196491), a Phase I trial of idecabtagene vicleucel (ide-cel, bb2121) for newly diagnosed high-risk multiple myeloma. Ide-cel is a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy which has demonstrated deep, durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. The primary endpoints of the trial are dose-limiting toxicity and safety. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar
Advisory role: GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm
